Oncotarget is a twice weekly peer-reviewed exposed access bio-medical journal started in the year 2010 and is published by Impact Journals. It is a multidisciplinary old journal and broadcasts papers on the internet with the aim of making scientific outcomes quickly and broadly accessible, to exploit the effect of study through an intuitive review, and also to eradicate the boundary between biomedical domains. Oncotarget nurtures uses of simple and clinical science to deal with ailment.
Through the leadership of the most successful persons in the field of science, the journal aids all researchers contribute to the development of science. Oncotarget’s main agenda is to endeavor to see a life which has no disease. Follow Oncotarget on Linkedin.
Inhibition of platelet purpose by liposomal nanoparticles prevents tumor metastasis
Extensive indication has disclosed that platelets encourage the progress of tumor metastatic by bringing epithelial-mesenchymal changeover of cancer cells and by protecting mingling tumor cells from immune-mediated removal. Due to this, obstructing platelet function signifies a possible fresh way of therapy concentrated on removing metastasis.
The nanoparticles (CREKA-Lipo-T) which are drug-loaded competently jammed the platelet-induced attainment of an aggressive phenotype by tumor cells and reserved platelet-tumor cell communication in vitro. Intravenously managed CREKA-Lipo-T efficiently beset growths within 24 hours, and reserved tumor metastasis minus overt side effects. So, the CREKA-Lipo invention gives the easy scheme for the well-organized distribution of anti-metastatic medications and displays substantial potential as a stage for new cancer therapeutics. Visit Oncotarget’s profile page at facebook.com
Two issues per week
Oncotarget now issues two publications per week. These contents are freely accessible in several high-profile indexes and archives. Working closely with the National Library of Medicine, Oncotarget is in the verge of gaining its aim of becoming the number one research journal to release a full issue to PubMed immediately after the publication was made online.
Oncortarget made this move with the belief that it is crucial to catch up with the tasks of the current time. With this reason, their work strives to be an academic journal renown for fast and extensive scale distribution of valued bio-medical research. Oncotarget is referred to as the journal by scientists for scientists. This move will enable it to remain a reserve assisting all researchers with their input to the growth of science.